Advertisement

Topics

Lilly's Abemaciclib On Par With Ibrance In Breast Cancer, But Not 'Clearly Superior'

07:56 EDT 11 Sep 2017 | SCRIP

Despite returning positive results in the MONARCH-3 trial, Lilly's breast cancer therapy abemaciclib has sparked mixed reactions at ESMO; the...

      

Related Stories

 

Original Article: Lilly's Abemaciclib On Par With Ibrance In Breast Cancer, But Not 'Clearly Superior'

NEXT ARTICLE

More From BioPortfolio on "Lilly's Abemaciclib On Par With Ibrance In Breast Cancer, But Not 'Clearly Superior'"

Quick Search
Advertisement
 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...